BR0208741A - Derivados de piperidina - Google Patents

Derivados de piperidina

Info

Publication number
BR0208741A
BR0208741A BR0208741-3A BR0208741A BR0208741A BR 0208741 A BR0208741 A BR 0208741A BR 0208741 A BR0208741 A BR 0208741A BR 0208741 A BR0208741 A BR 0208741A
Authority
BR
Brazil
Prior art keywords
piperidine derivatives
piperidine
derivatives
formula
pharmaceutical properties
Prior art date
Application number
BR0208741-3A
Other languages
English (en)
Inventor
Rainer Albert
Christian Bruns
Francois Nuninger
Markus Streiff
Gebhard Thoma
Hans-Guenter Zerwes
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0208741A publication Critical patent/BR0208741A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

"DERIVADOS DE PIPERIDINA". Derivados de piperidina de fórmula (I) como descritos na especificação têm propriedades farmacêuticas interessantes, por exemplo como inibidores de CCR5.
BR0208741-3A 2001-04-09 2002-04-08 Derivados de piperidina BR0208741A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0108876.4A GB0108876D0 (en) 2001-04-09 2001-04-09 Organic Compounds
PCT/EP2002/003871 WO2002081449A1 (en) 2001-04-09 2002-04-08 Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors

Publications (1)

Publication Number Publication Date
BR0208741A true BR0208741A (pt) 2004-06-22

Family

ID=9912541

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0208741-3A BR0208741A (pt) 2001-04-09 2002-04-08 Derivados de piperidina

Country Status (27)

Country Link
US (1) US20040142920A1 (pt)
EP (1) EP1379504B1 (pt)
JP (1) JP4366079B2 (pt)
KR (1) KR100616039B1 (pt)
CN (1) CN100469767C (pt)
AR (1) AR035815A1 (pt)
AT (1) ATE446950T1 (pt)
AU (1) AU2002302511B2 (pt)
BR (1) BR0208741A (pt)
CA (1) CA2439241C (pt)
CZ (1) CZ20032723A3 (pt)
DE (1) DE60234167D1 (pt)
EC (1) ECSP034765A (pt)
ES (1) ES2335393T3 (pt)
GB (1) GB0108876D0 (pt)
HU (1) HUP0303724A3 (pt)
IL (1) IL157428A0 (pt)
MX (1) MXPA03009220A (pt)
NO (1) NO20034324D0 (pt)
NZ (1) NZ528712A (pt)
PE (1) PE20021004A1 (pt)
PL (1) PL363011A1 (pt)
PT (1) PT1379504E (pt)
RU (1) RU2296751C2 (pt)
SK (1) SK12422003A3 (pt)
WO (1) WO2002081449A1 (pt)
ZA (1) ZA200306432B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1404667E (pt) 2001-07-02 2006-07-31 Astrazeneca Ab Derivados de piperidina uteis como moduladores da actividade do receptor de quimiocina
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
AR036366A1 (es) 2001-08-29 2004-09-01 Schering Corp Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
GB0122503D0 (en) 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0202838D0 (sv) * 2002-09-24 2002-09-24 Astrazeneca Ab Chemical compounds
ATE334680T1 (de) * 2002-10-04 2006-08-15 Ucb Sa 4-aminopiperidin-derivate, verfahren zur herstellung und ihre verwendung als arzneimittel
GB0223223D0 (en) * 2002-10-07 2002-11-13 Novartis Ag Organic compounds
EP1569931B1 (en) * 2002-12-13 2008-10-08 Smithkline Beecham Corporation Heterocyclic compounds as ccr5 antagonists
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
EP1616862A4 (en) * 2003-04-18 2008-07-16 Ono Pharmaceutical Co HETEROCYCLIC NITROGEN COMPOUND AND USE THEREOF
FR2854158B1 (fr) * 2003-04-25 2006-11-17 Sanofi Synthelabo Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
EP1633737A1 (en) * 2003-06-13 2006-03-15 Schering Aktiengesellschaft Quinolyl amide derivatives as ccr-5 antagonists
JP4757802B2 (ja) * 2003-11-03 2011-08-24 シェーリング コーポレイション ケモカインレセプターの阻害剤として有用なビピペリジニル誘導体
US7498346B2 (en) * 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
US7479496B2 (en) 2004-02-19 2009-01-20 Bristol-Myers Squibb Company Substituted spiro azabicyclics as modulators of chemokine receptor activity
US7288563B2 (en) 2004-02-19 2007-10-30 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7381738B2 (en) 2004-02-19 2008-06-03 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7230022B2 (en) 2004-02-19 2007-06-12 Bristol-Myers Squibb Company Substituted fused bicyclic amines as modulators of chemokine receptor activity
JP2008528477A (ja) * 2005-01-20 2008-07-31 ファイザー・リミテッド 化合物
KR20080037655A (ko) 2005-07-21 2008-04-30 아스트라제네카 아베 신규 피페리딘 유도체
WO2008030853A2 (en) * 2006-09-06 2008-03-13 Incyte Corporation Combination therapy for human immunodeficiency virus infection
WO2008070758A1 (en) * 2006-12-06 2008-06-12 Genzyme Corporation Chemokine receptor binding compounds
TW201100398A (en) 2009-03-31 2011-01-01 Arqule Inc Substituted indolo-pyridinone compounds
JP2014518610A (ja) 2011-03-09 2014-08-07 リチャード ジー． ペステル 前立腺癌細胞系、遺伝子シグネチャー及びその使用
WO2013173312A1 (en) * 2012-05-14 2013-11-21 Pestell Richard G Using modulators of ccr5 for treating cancer
JOP20200052A1 (ar) 2013-12-19 2017-06-16 Bayer Pharma AG بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c
CA2934133A1 (en) 2013-12-19 2015-06-25 Bayer Pharma Aktiengesellschaft Substituted piperidinyl-tetrahydroquinolines
EP3083610A1 (de) 2013-12-19 2016-10-26 Bayer Pharma Aktiengesellschaft Substituierte bipiperidinyl-derivate als adrenrezeptor alpha 2c antagonisten
EP3083594A1 (de) 2013-12-19 2016-10-26 Bayer Pharma Aktiengesellschaft Substituierte bipiperidinyl-derivate als adrenorezeptor alpha 2c antagonisten

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW531537B (en) * 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
US5952349A (en) * 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
CZ82399A3 (cs) * 1996-09-10 1999-06-16 Dr. Karl Thomae Gmbh Modifikované aminokyseliny, způsob jejich výroby a farmaceutický prostředek s jejich obsahem
DE19637043A1 (de) * 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Neue Aminoalkoholderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel und Reagenzien
DE19643331A1 (de) * 1996-10-21 1998-04-23 Thomae Gmbh Dr K 1-(4-Piperidinyl)-piperidinylene, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
ES2246233T3 (es) * 1999-05-04 2006-02-16 Schering Corporation Derivados de piperidina utiles como antagonistas de ccr5.
US6391865B1 (en) * 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
CA2382880C (en) * 1999-06-11 2008-10-14 Paul E. Finke N-cyclopentyl modulators of chemokine receptor activity
US6638950B2 (en) * 2000-06-21 2003-10-28 Bristol-Myers Squibb Pharma Company Piperidine amides as modulators of chemokine receptor activity
US20020165223A1 (en) * 2000-09-14 2002-11-07 Greenlee William J. Substituted urea neuropeptide Y Y5 receptor antagonists
AR036366A1 (es) * 2001-08-29 2004-09-01 Schering Corp Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
GB0223223D0 (en) * 2002-10-07 2002-11-13 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
CA2439241C (en) 2010-06-08
NO20034324L (no) 2003-09-26
JP4366079B2 (ja) 2009-11-18
ES2335393T3 (es) 2010-03-26
CN100469767C (zh) 2009-03-18
EP1379504B1 (en) 2009-10-28
ATE446950T1 (de) 2009-11-15
US20040142920A1 (en) 2004-07-22
KR20030087066A (ko) 2003-11-12
IL157428A0 (en) 2004-03-28
EP1379504A1 (en) 2004-01-14
CZ20032723A3 (cs) 2003-12-17
SK12422003A3 (sk) 2004-05-04
CA2439241A1 (en) 2002-10-17
AU2002302511B2 (en) 2005-08-04
PE20021004A1 (es) 2003-01-03
DE60234167D1 (de) 2009-12-10
NZ528712A (en) 2005-07-29
ECSP034765A (es) 2003-10-28
PL363011A1 (en) 2004-11-15
MXPA03009220A (es) 2004-01-29
NO20034324D0 (no) 2003-09-26
ZA200306432B (en) 2004-06-04
HUP0303724A3 (en) 2007-09-28
AR035815A1 (es) 2004-07-14
RU2003130642A (ru) 2005-04-10
WO2002081449A1 (en) 2002-10-17
KR100616039B1 (ko) 2006-08-28
CN1501915A (zh) 2004-06-02
PT1379504E (pt) 2010-01-04
GB0108876D0 (en) 2001-05-30
RU2296751C2 (ru) 2007-04-10
HUP0303724A2 (hu) 2004-03-01
JP2004525174A (ja) 2004-08-19

Similar Documents

Publication Publication Date Title
BR0208741A (pt) Derivados de piperidina
SE9904652D0 (sv) Novel Compounds
ATE433447T1 (de) Pyrimiidinverbindungen
MXPA03011039A (es) Nuevos compuestos heterociclicos, su preparacion y uso como medicamentos, particularmente como agentes anti-bacterianos.
MX2007011695A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
SE0301700D0 (sv) Novel compounds
IS6658A (is) Ný efnasambönd
DE60003863D1 (de) Dioxocyclopentylhydroxamsäure
ATE296826T1 (de) Pyrazolo(1,5)pyridinderivate
HK1155146A1 (zh) 作為藥物活性劑的茚衍生物
DE60211223D1 (de) Piperidinderivate als Kalium-Kanal Blockers
ATE316083T1 (de) Adamantanderivate
BR0107888A (pt) Pirrolidinas 1,3-dissubstituidas como antagonistas de alfa-2adrenorreceptor
ES2243579T3 (es) Derivados de pirazolopirideno.
MX2007011698A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
NO20021859D0 (no) Nye digosakkarider, deres fremstilling samt farmasöytiske preparater
ATE386725T1 (de) Heterocyclylverbindungen
SE0302139D0 (sv) Novel compounds
SE0101932D0 (sv) Pharmaceutical combinations
IL173809A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
SE0003476D0 (sv) Compounds
SE0303280D0 (sv) Novel compounds
BRPI0415285A (pt) derivados de aminoalcanol
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 10A. ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.